利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.041 秒)

    Three dimensional semiconductor memory devices and methods of fabricating the same
    11.
    发明授权
    Three dimensional semiconductor memory devices and methods of fabricating the same 有权
    三维半导体存储器件及其制造方法

    公开(公告)号：US08952443B2

    公开(公告)日：2015-02-10

    申请号：US13222173

    申请日：2011-08-31

    申请人： Sung-Il Chang ,  Young Woo Park ,  Jae Goo Lee

    发明人： Sung-Il Chang ,  Young Woo Park ,  Jae Goo Lee

    IPC分类号： H01L29/792 ,  H01L27/115 ,  H01L21/28

    CPC分类号： H01L27/11582 ,  H01L21/28273 ,  H01L21/28282 ,  H01L21/31111 ,  H01L27/11551 ,  H01L27/11556 ,  H01L27/11578 ,  H01L29/42324 ,  H01L29/4234

    摘要： A 3D semiconductor device includes an electrode structure has electrodes stacked on a substrate, semiconductor patterns penetrating the electrode structure, charge storing patterns interposed between the semiconductor patterns and the electrode structure, and blocking insulating patterns interposed between the charge storing patterns and the electrode structure. Each of the blocking insulating patterns surrounds the semiconductor patterns, and the charge storing patterns are horizontally spaced from each other and configured in such a way as to each be disposed around a respective one of the semiconductor patterns. Also, each of the charge storing patterns includes a plurality of horizontal segments, each interposed between vertically adjacent ones of the electrodes.

    摘要翻译： 一种3D半导体器件包括：电极结构，其具有堆叠在基板上的电极，穿透电极结构的半导体图案，插入在半导体图案和电极结构之间的电荷存储图案，以及插入在电荷存储图案和电极结构之间的绝缘图案。 每个隔离绝缘图案包围半导体图案，并且电荷存储图案彼此水平间隔并且以这样的方式配置，以使得每个隔离绝缘图案围绕相应的一个半导体图案设置。 而且，每个电荷存储图案包括多个水平段，每个水平段插入垂直相邻的电极之间。

    PHARMACEUTICAL COMPOSITION CONTAINING AN ENDOCYTIC MOTIF AND PROTEIN TRANSDUCTION DOMAINS FOR PREVENTING OR TREATING CANCER
    19.
    发明申请
    PHARMACEUTICAL COMPOSITION CONTAINING AN ENDOCYTIC MOTIF AND PROTEIN TRANSDUCTION DOMAINS FOR PREVENTING OR TREATING CANCER 有权
    含有内源性MOTIF的蛋白质组合物和用于预防或治疗癌症的蛋白质转染域

    公开(公告)号：US20140066375A1

    公开(公告)日：2014-03-06

    申请号：US14002600

    申请日：2012-03-02

    申请人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

    发明人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

    IPC分类号： C07K7/08 ,  C07K14/00

    CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/00 ,  C07K14/4753 ,  C07K2319/10

    摘要： The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

    摘要翻译： 本发明涉及一种新的内吞基序，特别涉及包含由SEQ ID NO：1的氨基酸序列表示的基序的融合多肽。 1和蛋白质转导结构域，用于预防或治疗包括其的癌症的药物组合物，以及治疗癌症的方法，包括施用组合物的步骤。 本发明通过特异性抑制c-Met内吞作用并有效抑制与各种癌细胞的转移和生长相关的HGF / c-Met信号通路，显示抑制癌转移，浸润，血管生成和生长的作用。 因此，本发明可以应用于各种癌症的抗癌剂。

    Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient
    20.
    发明申请
    Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient 有权
    含有DLK1-Fc融合蛋白作为有效成分的抗癌转移的组成

    公开(公告)号：US20130202592A1

    公开(公告)日：2013-08-08

    申请号：US13142818

    申请日：2010-04-13

    申请人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

    发明人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

    IPC分类号： C07K16/00 ,  C07K14/435

    CPC分类号： C07K16/00 ,  C07K14/435 ,  C07K14/475 ,  C07K2319/30 ,  Y10S424/809 ,  Y10S530/866

    摘要： A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

    摘要翻译： 构建了包含DLK1和IgG抗体Fc结构域基因的细胞外可溶性域基因的重组表达载体，并且在293E细胞上表达和纯化DLK1-Fc融合蛋白。 本发明通过确认DLK1-Fc融合蛋白对癌细胞的迁移显着减少并且还计算药代动力学参数，证实了作为抑制癌症转移的药物的功效。 DLK1-Fc融合蛋白具有比非融合蛋白更高的稳定性，显着降低各种癌细胞系的迁移，即使在小浓度下也能提供优异的癌转移抑制作用。 因此，DLK1-Fc融合蛋白可以有效地用作抑制癌症转移的组合物的有效成分。